Sustained Virological Response in the Antiviral Therapy of Chronic Hepatitis C: Is There a Predictive Value of Interferon-Induced Depression?Schäfer A.a · Scheurlen M.a · Weissbrich B.b · Schöttker K.a · Kraus M.R.a
aDepartment of Gastroenterology and Hepatology, Medizinische Klinik und Poliklinik II and bInstitute for Virology and Immunobiology, University of Würzburg, Würzburg, Germany
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: The study objective was to determine the contribution of cytokine-induced depression to a predictive model of sustained virological response (SVR) in chronic hepatitis C. Methods: One hundred and one therapy-naïve hepatitis C virus (HCV) outpatients received treatment with peginterferon alfa-2b and ribavirin. Neuropsychiatric side effects were monitored prospectively (Hospital Anxiety and Depression Scale, DSM-IV criteria for major depression). SVR was defined as a failure to detect HCV by PCR 24 weeks after therapy. Results: SVR rate was 72.3% (73 of 101 patients). Classification data and the extent of interferon-induced depression were not significantly linked to SVR. Virus genotype (p = 0.045) and gender (p = 0.016) contributed significantly to a logistic regression model. Mean (p = 0.811) and maximum (p = 0.744) depression increases were no significant predictors of SVR. Major depression rates (DSM-IV criteria) were 12.3% (9 of 73 patients) in the subgroup with SVR and 10.7% (3 of 28) in patients without SVR. Conclusions: We found no significant association between depression and the efficacy of antiviral treatment in chronic hepatitis C. Interferon-induced depressive symptoms are important to be monitored and treated if necessary; however, they cannot be used to predict therapy success.
© 2007 S. Karger AG, Basel
- Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958–965.
- Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975–982.
- Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346–355.
- Kraus MR, Schäfer A, Faller H, Csef H, Scheurlen M: Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003;64:708–714.
- Kartal ED, Colak H, Ozgunes I, Usluer G: Exacerbation of psoriasis due to peginterferon alpha-2b plus ribavirin treatment of chronic active hepatitis C. Chemotherapy 2005;51:167–169.
- Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Chaneac M, Reddy KR: Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43:425–433.
- Ferenci P: Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis 2004;24(suppl 2):25–31.
- Kim TH, Kim KA, Lim YS, Gwak GY, Yoon JH, Kang GH, Lee HS: Prediction of treatment outcome in chronic hepatitis C patients based on early viral dynamics during high-dose induction interferon and ribavirin therapy. Intervirology 2005;48:230–238.
- Watkins-Riedel T, Ferenci P, Steindl-Munda P, Gschwantler M, Mueller C, Woegerbauer M: Early prediction of hepatitis C virus (HCV) infection relapse in nonresponders to primary interferon therapy by means of HCV RNA whole-blood analysis. Clin Infect Dis 2004;39:1754–1760.
- Loftis JM, Socherman RE, Howell CD, Whitehead AJ, Hill JA, Dominitz JA, Hauser P: Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. Neurosci Lett 2004;365:87–91.
- Raison CL, Broadwell SD, Borisov AS, Manatunga AK, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH: Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 2005;19:23–27.
- Maddock C, Landau S, Barry K, Maulayah P, Hotopf M, Cleare AJ, Norris S, Pariante CM: Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response. Mol Psychiatry 2005;10:332–333.
Herrmann C, Buss U, Snaith RP: HADS-D. Hospital Anxiety and Depression Scale – Deutsche Version. Ein Fragebogen zur Erfassung von Angst und Depressivität in der somatischen Medizin. Bern, Huber, 1995.
- Herrmann C: International experiences with the Hospital Anxiety and Depression Scale – a review of validation data and clinical results. J Psychosom Res 1997;42:17–41.
SPSS: SPSS für Windows 12.0.2. Chicago, SPSS , 2004.
- Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O’Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666–1672.
- McHutchison JG, Fried MW: Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin Liver Dis 2003;7:149–161.
- Loftis JM, Hauser P, Rifai MA: The association between viral clearance and depression in patients with hepatitis C receiving interferon-alpha and ribavirin. Brain Behav Immun 2005;19:271–274.
- Douglas SD: Hepatitis C, depressive symptoms, viral load, and therapy: interactions and reactions. Brain Behav Immun 2005;19:20–22.
- Lee SS: Review article: indicators and predictors of response to anti-viral therapy in chronic hepatitis C. Aliment Pharmacol Ther 2003;17:611–621.
- Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, Heldwein W, Soyka M, Grunze H, Koenig A, Loeschke K: Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003;37:443–451.
- Schaefer M, Schwaiger M, Garkisch AS, Pich M, Hinzpeter A, Uebelhack R, Heinz A, van Boemmel F, Berg T: Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005;42:793–798.
- Castro FJ, Esteban JI, Juarez A, Sauleda S, Viladomiu L, Martell M, Moreno F, Allende H, Esteban R, Guardia J: Early detection of nonresponse to interferon plus ribavirin combination treatment of chronic hepatitis C. J Viral Hepat 2002;9:202–207.
- Carlsson T, Reichard O, Norkrans G, Blackberg J, Sangfelt P, Wallmark E, Weiland O: Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. J Viral Hepat 2005;12:473–480.
- Kraus MR, Schäfer A, Faller H, Csef H, Scheurlen M: Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1091–1099.
- Kraus MR, Schäfer A, Al-Taie O, Scheurlen M: Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005;12:96–100.
- Horsmans Y: Chronic hepatitis C, depression and interferon. J Hepatol 2005;42:788–789.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.